Clinical trial · Interventional
Platelet-rich Plasma and Synovial Cytokines in Knee Osteoarthritis
Assessments of Therapeutic Effects of Platelet-rich Plasma in Knee Osteoarthritis: Possible Role of Inflammatory Cytokines
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective study was performed on 90 patients were included and categorized into mild (30 cases, moderate (30 cases) and severe (30 cases) knee OA. Three intra-articular (I.A) injections of PRP, 2 weeks a part, were received. Pain score and MRI Osteoarthritis Knee Score (MOAKS) were assessed. Serial synovial fluid cytokines assays in the form of Tumor necrosis factor-α (TNF-α) and Macrophage migration inhibitory factor (MIF), were performed using commercially available ELISA assay kits. The assays were performed pre-injection (S1), two weeks from the 1st I.A injection and two weeks from the 2nd I.A injection (S3) for all included patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Knee Osteoarthritis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intra-articular injection of platelet-rich plasma | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Mild knee osteoarthritis
- description
- 30 patients had mild knee osteoarthritis
- interventionNames
- Drug: Intra-articular injection of platelet-rich plasma
- type
- ACTIVE_COMPARATOR
- label
- Moderate knee osteoarthritis
- description
- 30 patients had moderate knee osteoarthritis
- interventionNames
- Drug: Intra-articular injection of platelet-rich plasma
- type
- ACTIVE_COMPARATOR
- label
- Severe knee osteoarthritis
- description
- 30 patients had severe knee osteoarthritis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: • All patients have unilateral knee OA Exclusion Criteria: * Polyarticular disease. * Knee arthroscopy in the previous year. * HA or steroid IA penetration in the preceding 3 months. * History of infectious disease and autoimmune disorders such as diabetes, rheumatoid arthritis. * Hematologic diseases (coagulopathy). * Serious cardiovascular diseases , infections or immunodepression. * Anticoagulant therapy or an anti-aggregating agent. * Uuse of non-steroidal anti-inflammatory drugs 2 weeks prior to blood sampling. * \< 10 g / dL of hemoglobin
References
Publications (3)
- RESULTTaniguchi Y, Yoshioka T, Kanamori A, Aoto K, Sugaya H, Yamazaki M. Intra-articular platelet-rich plasma (PRP) injections for treating knee pain associated with osteoarthritis of the knee in the Japanese population: a phase I and IIa clinical trial. Nagoya J Med Sci. 2018 Feb;80(1):39-51. doi: 10.18999/nagjms.80.1.39. PMID 29581613
- RESULTHunter DJ, Guermazi A, Lo GH, Grainger AJ, Conaghan PG, Boudreau RM, Roemer FW. Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score). Osteoarthritis Cartilage. 2011 Aug;19(8):990-1002. doi: 10.1016/j.joca.2011.05.004. Epub 2011 May 23. PMID 21645627
- RESULTKatz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999 Apr;79(2):231-52. doi: 10.1016/s0039-6109(05)70381-9. PMID 10352653